Barinthus Biotherapeutics (STU:2AB) PS Ratio: (As of Jul. 01, 2026)


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.57
GF Value €0.96
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Barinthus Biotherapeutics's share price is €0.565. Barinthus Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00. Hence, Barinthus Biotherapeutics's PS Ratio for today is .

The historical rank and industry rank for Barinthus Biotherapeutics's PS Ratio or its related term are showing as below:

During the past 7 years, Barinthus Biotherapeutics's highest PS Ratio was 1468.75. The lowest was 0.16. And the median was 2.92.

STU:2AB's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.515
* Ranked among companies with meaningful PS Ratio only.

Barinthus Biotherapeutics's Revenue per Sharefor the three months ended in Mar. 2026 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Barinthus Biotherapeutics was -100.00% per year.

During the past 7 years, Barinthus Biotherapeutics's highest 3-Year average Revenue per Share Growth Rate was 236.20% per year. The lowest was -94.10% per year. And the median was 71.05% per year.

Back to Basics: PS Ratio


Barinthus Biotherapeutics  (STU:2AB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Barinthus Biotherapeutics PS Ratio Related Terms


Barinthus Biotherapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics PS Ratio Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial 1,111.00 2.01 175.71 3.18 0.00

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 2.45 0.00 0.00 0.00

STU:2AB vs VTGN, PSTV, PVCT: PS Ratio Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's PS Ratio falls into.


STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Barinthus Biotherapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.565/0
=

Barinthus Biotherapeutics's Share Price of today is €0.565.
Barinthus Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.57 is trading 41.1% below its estimated GF Value™ of €0.96.

Key valuation signals for STU:2AB:

  • PS Ratio:
  • GF Value™: €0.96 vs. price of €0.57 (41.1% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57
Price
€0.96
GF Value